How has Protagonist Therapeutics's other current liabilities changed year-over-year?

Protagonist Therapeutics's other current liabilities increased by 8.7% year-over-year, from -$11.82M to -$10.79M.

Protagonist Therapeutics PTGX Other Current Liabilities

ImmunityBio, Inc.IBRX

——

Revenue$56.4M+99.0%

Operating income-$3.6M+81.1%

Net income$3.8M+132%

EPS (diluted)$0.05+126%

Cash & equivalents$193.7M+38.7%

Total debt$9.8M-13.9%

Total equity$655.5M-4.9%

Total assets$697.5M-6.0%

Operating cash flow-$48.9M-139%

CapEx$215.0K-60.6%

Free cash flow-$49.2M-139%

Market cap$7.26B+127%

Enterprise value$7.07B+130%

P/S98×+82.6×

Operating margin-192.4%-205pp

Net margin-154.9%-182pp

FCF margin-12,264.3%-12,527pp

Return on equity-17.1%-26.1pp

Debt / equity0×0.0×

Current ratio17.8×+0.5×

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities.

The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Protagonist Therapeutics's other current liabilities?: Protagonist Therapeutics (PTGX) reported other current liabilities of -$10.79M in Q1 2026.
How has Protagonist Therapeutics's other current liabilities changed year-over-year?: Protagonist Therapeutics's other current liabilities increased by 8.7% year-over-year, from -$11.82M to -$10.79M.